IL2, interleukin 2, 3558

N. diseases: 950; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE Interleukin-2 (IL-2) and IL-15 play pivotal roles in T cell activation, apoptosis, and survival, and are implicated in leukemias and autoimmune diseases. 31570576 2019
CUI: C0023418
Disease: leukemia
leukemia
0.400 GeneticVariation disease BEFREE Few studies have been published analyzing IFNG +874 T/A and IL2 -330 G/T in this type of leukemia. 30212785 2018
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE In a phase IV trial (Re:Mission Trial, NCT01347996, http://www.clinicaltrials.gov ) 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received ten consecutive 3-week cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2) to prevent relapse of leukemia in the post-consolidation phase. 28721449 2017
CUI: C0023418
Disease: leukemia
leukemia
0.400 AlteredExpression disease BEFREE Overexpression of interleukin 2 receptor (IL2R) in hematological malignancies has been utilized to target leukemia. 26984209 2016
CUI: C0023418
Disease: leukemia
leukemia
0.400 GeneticVariation disease BEFREE Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. 25109334 2015
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE Blockade of IL2 and IL15 using monoclonal antibodies has been reported to be of value in the treatment of patients with leukemia, autoimmune disorders, and in the prevention of allograft rejection. 25736261 2015
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE To search for these molecules we aligned IL-2 regulated genes detected by Affymetrix gene expression microarrays with the STAT5 cistrome identified by chip-on-ChIP analysis in an IL-2-dependent human leukemia cell line, Kit225. 23451206 2013
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE Possible explanations for these outcomes include immunologic response to sepsis by a leukemia-specific T-cell response or the release of various cytokines, such as tumor necrosis factor and interleukin-2, during infections. 22627572 2012
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE We believe our results provide important mechanistic insights for the potential use of IL-2-expanded CB-derived NK cells for adoptive immune therapy in leukemia. 20664358 2010
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - Construction and characterization. 20580754 2010
CUI: C0023418
Disease: leukemia
leukemia
0.400 AlteredExpression disease BEFREE One agent, containing human interleukin-2 and truncated diphtheria toxin (denileukin diftitox), has been approved for use in cutaneous T-cell lymphoma, and has shown activity in other hematologic malignancies, including leukemias and lymphomas. 19344187 2009
CUI: C0023418
Disease: leukemia
leukemia
0.400 Therapeutic disease CTD_human Novel role of triazenes in haematological malignancies: pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. 17500047 2007
CUI: C0023418
Disease: leukemia
leukemia
0.400 AlteredExpression disease LHGDN Concentration of IL-2, IL-6, IL-8, IL-10 and TNF-alpha in children with acute lymphoblastic leukemia after cessation of chemotherapy. 15152368 2004
CUI: C0023418
Disease: leukemia
leukemia
0.400 AlteredExpression disease BEFREE Earlier we have shown that interleukin-2 (IL-2)-activated MNC from cord blood have significant cytotoxic activity against human leukemia and breast cancer cells in vitro and in vivo, compared to MNC from peripheral blood. 12494899 2003
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE The goal of this study was to define the potential to use canine lymphoma and leukemia as suitable models to refine therapeutic approaches targeting the interleukin-2 receptor (IL-2R). 11924909 2002
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE Our results suggest that the effects of physiologically achievable concentrations of butyrate on IL-2R expression could be exploited to enhance the susceptibility of intermediate and low-affinity IL-2R expressing leukemia cells to DAB(389)IL-2. 12443879 2002
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. 12473581 2002
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE IL-2-dependent clones established from the DN alphabeta T cell population in the PEC of IL-2 receptor alpha-chain transgenic B6 mice exhibited potent cytotoxicity against a series of B cell lineage leukemias and myelomas, such as CD5+BCL1 and MOPC, without affecting NK-susceptible targets. 8892624 1996
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE The results suggest that although reduction in the proportion of leukaemia in contaminated marrow can be detected after incubation with IL-2 for 24 h, complete elimination of minimal residual disease requires longer incubation times. 7533866 1995
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE Four aspects are discussed: (i) the generalized immune activation induced by the systemic administration of cytokines, in particular, interleukin-2; (ii) the specific T cell-mediated reactions against tumour cells through the recognition of tumour-associated molecules, 1) and tyrosinase proteins described in melanomas, and minor histocompatibility antigens in the setting of allogenic bone marrow transplantation for leukaemia; (iii) the potentially significant but still hypothetical immune-mediated recognition of molecules either tumour-associated or transformation-related (including altered oncogenic proteins); and (iv) the role of co-stimulatory molecules in the induction of tumour-specific immunity. 8535054 1995
CUI: C0023418
Disease: leukemia
leukemia
0.400 AlteredExpression disease BEFREE Expression of human T-cell leukaemia virus type I and associated antigens, and interleukin-2 and receptor in lymph nodes of adult T-cell leukaemia/lymphoma. 7812510 1994
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE IL-2-dependent ATL cell lines with phenotypes differing from the original leukemia cells. 1861543 1991
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. 1698543 1990
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE IL-1-induced production of IL-2 and IFN-gamma in subclones of human T-cell derived leukaemia HSB.2 cells: regulation by phytohaemagglutinin-mediated (poly)phosphoinositide breakdown and cyclic AMP. 2172158 1990
CUI: C0023418
Disease: leukemia
leukemia
0.400 Biomarker disease BEFREE These data presented the possibility that lck gene product may be one of the intervening molecules which transduce the signal from the IL-2R into the cell interior, and play an important role in the pathophysiology of adult T cell leukemia, especially in the transition of these leukemias from the IL-2-dependent stage to IL-2-independent one for their growth. 2786034 1989